Breaking News Gives (NYSE: MAIA) A Green Boost Early (Low Float + Strong Analyst Targets)

*Sponsored

September 5th

Greetings, Friend!

MAIA Biotechnology, Inc. (NYSE American: MAIA) is making green moves early on the heels of breaking news.

Check it out:

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC)

CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract titled “Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS” was selected for poster presentation at the 2025 IASLC World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025, in Barcelona, Spain.

“We are proud to accept IASLC’s invitation to present our exceptional ateganosine (THIO) data at its prestigious World Conference on Lung Cancer. Our participation gives us the opportunity to meet with elite scientists, researchers, and global industry leaders about our shared purpose in driving innovation in lung cancer treatments,” said MAIA Chairman and CEO Vlad Vitoc, M.D.

“Ateganosine is demonstrating substantial efficacy in our ongoing THIO-101 trial, with a median overall survival (OS) of 17.8 months with a 95% confidence interval (CI) lower bound of 12.5 months. We believe our novel anticancer agent could become a breakthrough treatment for those suffering from late-stage non-small cell lung cancer,” said MAIA’s Senior Medical Director Victor Zaporojan, M.D. “We look forward to further discussing our observed progression free survival (PFS) at this year’s World Conference on Lung Cancer.”

...

Read the full article here.

Here's a couple things to consider on top of the news...

#1. This is a low float idea. With fewer than 29Mn shares in its float, volatility potential could be significantly heightened for MAIA on a daily basis (and especially after positive news developments).

#2. A pair of analyst targets point to triple-digit upside potential. This recent note from Diamond Equity Research suggests a $10.27 target which implies over 500% potential upside.

Take a moment now to review my initial (NYSE American: MAIA) report below and consider this profile for your radar.

-----

A leading clinical-stage biopharmaceutical company at the forefront of cancer research has recently drawn new attention following the release of an independent update note from Diamond Equity Research.

Focused on developing next-generation treatments that directly target some of the most challenging oncology indications, this company continues to make meaningful progress in areas of high unmet medical need.

With its innovative approach to enhancing immune responses and improving patient survival outcomes, the latest research update underscores why this story could really start gaining some serious momentum.

And with 7 potential catalysts including a low float, strong analyst targets, and news of receiving FDA fast track designation, this NYSE American profile has taken control of my top watchlist spot.

Oh, yeah! Brought into focus back towards the end of April, this profile moved from an alert price of roughly $1.95 to a high of $2.74 in May.

That marks a short-term move of approximately 40%.

For Friday, consider this NYSE American profile again for your radar:

*MAIA Biotechnology, Inc. (NYSE American: MAIA)*

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.

Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

Find Key Company Details Here: MAIA Website. MAIA Presentation.

7 Explosive Potential Catalysts Could Generate Breakout Buzz For (NYSE American: MAIA)

#1. An Update Note From Diamond Equity Research Suggests MAIA To Have Significant Upside Potential From Current Chart Levels.

Check out this update note that was shared a few weeks back:

From MAIA's closing valuation on Thursday, this $10.27 target suggests an upside potential of over 500%!

Critical Report Info:

Valuation: Recent updates further de-risk the THIO program in third-line NSCLC. The Phase 2 THIO-101 dataset now shows a median overall survival of 17.8 months in the intent-to-treat cohort with a generally tolerable safety profile, and a confirmed partial response after 20 months of therapy supports durability. Fast Track designation for ateganosine in NSCLC and a master clinical supply agreement with Roche to evaluate the THIO–atezolizumab sequence enhance the regulatory path and partnering visibility. We continue to expect initiation of the pivotal THIO-104 study in the second half of 2025 with an accelerated approval filing targeted for 2026, contingent on THIO-101 outcomes, while planned multitumor studies expand the addressable opp. We have revised our valuation model to incorporate the most recent financial results, updated share count, and re-evaluated the comparable company analysis, yielding a valuation of $10.27 per share, contingent on successful execution by the company.

#2. A Major Analyst Target Suggest Serious Upside Potential (Triple-Digit!).

Noble Capital Markets - $14.00 Target - (Potential upside of 800+% from Thursday's close.)

Key Report Details:

Conclusion. Roche becomes the third pharmaceutical company to make a supply agreement with MAIA to test a checkpoint inhibitor in combination with THIO. We believe this shows that potential partners have noticed the data showing improved overall survival (OS), progression free survival (PFS), and the side effect profile. Clinical data from the three of the eight approved checkpoint inhibitors could make bidding for a marketing partnership more competitive. We are reiterating our Outperform rating and $14 price target.

#3. MAIA Has A Relatively Low Float (Volatility Potential May Be Explosive).

Sporting a float of roughly 28.34Mn shares, according to Yahoo Finance, volatility potential could pop up in a flash.

#4. MAIA Biotechnology Expands Global Leadership With European Cancer Therapy Patent.

MAIA Biotechnology, Inc. achieved a major milestone with the European Patent Office granting protection for its novel telomere-targeting anticancer agents.

This new patent covers ateganosine-based analogues, designed to disrupt telomeres, halt cancer cell growth, and enhance anticancer activity with higher specificity.

The innovation strengthens MAIA’s intellectual property portfolio across Europe, securing rights in 19 countries.

#5. MAIA Achieves Fast Track FDA Designation For Ateganosine Lung Cancer Therapy.

MAIA Biotechnology, Inc. received FDA Fast Track designation for ateganosine (THIO) in treating non-small cell lung cancer (NSCLC), a $34Bn market with significant unmet need.

Ateganosine, a first-in-class telomere-targeting molecule, disrupts cancer cell survival and enhances immune response.

This designation accelerates potential FDA approval, strengthening MAIA’s competitive edge.

If approved, ateganosine could reach market, advance cancer care, and secure exclusivity, underscoring MAIA’s pioneering role in innovative oncology treatments.

#6. MAIA Expands Global Phase 2 Trial Advancing Ateganosine Lung Cancer Therapy.

MAIA Biotechnology, Inc. announced the dosing of the first patient in Taiwan for the expansion of its pivotal Phase 2 THIO-101 trial, advancing ateganosine (THIO) for advanced non-small cell lung cancer (NSCLC).

This milestone extends the study’s reach across Asia and Europe, broadening access to a larger patient pool.

Interim results show ateganosine delivers a median overall survival of 17.8 months in heavily pre-treated patients—far surpassing the 5–6 months seen with chemotherapy.

Well-tolerated and first-in-class, ateganosine positions MAIA for leadership and first-mover advantage in the multi-Bn-dollar NSCLC market.

#7. MAIA Has Multiple, Potential Value-Driving Milestones In The Near Future.

-----

Coverage on MAIA Biotechnology, Inc. (NYSE American: MAIA) is now officially underway.

When updates are available, I'll get them out to you quickly. Talk again soon.

All the best,

Dane James

Editor Market Pulse Today

(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 09/05/2025 and ending on 09/05/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid forty two thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MAIA:US).

Please see important disclosure information here: https://marketpulsetoday.com/disclosure/maia-nxwdz/#details

Breaking News Gives (NYSE: MAIA) A Green Boost Early (Low Float + Strong Analyst Targets)

Post a Comment

Contact Form